CRIS Current Research Information System

MACCHINI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.278
NA - Nord America 3.255
EU - Europa 2.500
AF - Africa 225
SA - Sud America 194
Continente sconosciuto - Info sul continente non disponibili 192
OC - Oceania 4
Totale 9.648
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.198
VN - Vietnam 999
CN - Cina 841
SG - Singapore 807
IT - Italia 566
GB - Regno Unito 490
SE - Svezia 308
DE - Germania 262
HK - Hong Kong 176
FR - Francia 153
BR - Brasile 135
IN - India 135
RU - Federazione Russa 121
CH - Svizzera 111
UA - Ucraina 107
IE - Irlanda 92
NL - Olanda 77
KR - Corea 60
FI - Finlandia 57
BD - Bangladesh 56
JP - Giappone 56
ZA - Sudafrica 55
CI - Costa d'Avorio 44
TG - Togo 41
NG - Nigeria 37
EE - Estonia 35
AT - Austria 31
CA - Canada 24
PH - Filippine 24
SC - Seychelles 22
TH - Thailandia 22
BG - Bulgaria 21
AR - Argentina 19
BE - Belgio 19
JO - Giordania 16
MX - Messico 15
ID - Indonesia 14
PL - Polonia 12
TR - Turchia 11
EC - Ecuador 9
PK - Pakistan 9
ES - Italia 8
IR - Iran 8
CL - Cile 7
JM - Giamaica 7
TW - Taiwan 7
CO - Colombia 6
HR - Croazia 6
VE - Venezuela 6
DZ - Algeria 5
EG - Egitto 5
IQ - Iraq 5
LT - Lituania 5
NI - Nicaragua 5
PT - Portogallo 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
NP - Nepal 4
PY - Paraguay 4
AU - Australia 3
CR - Costa Rica 3
GR - Grecia 3
KE - Kenya 3
PE - Perù 3
UY - Uruguay 3
BO - Bolivia 2
BY - Bielorussia 2
CM - Camerun 2
CZ - Repubblica Ceca 2
IL - Israele 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
MY - Malesia 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BT - Bhutan 1
BW - Botswana 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
GP - Guadalupe 1
KH - Cambogia 1
ME - Montenegro 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MR - Mauritania 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
SN - Senegal 1
SV - El Salvador 1
TN - Tunisia 1
Totale 9.455
Salva come PNG Salva come JPEG
Città #
Singapore 542
Southend 437
Ashburn 362
Chandler 237
Fairfield 208
Dong Ket 204
Hanoi 177
Ho Chi Minh City 175
Hong Kong 163
Santa Clara 163
San Jose 143
Princeton 118
New York 117
Houston 109
Bern 105
Beijing 104
Wilmington 101
Hefei 93
Dublin 92
Ann Arbor 91
Boardman 82
Woodbridge 80
Council Bluffs 74
Seattle 71
Dallas 68
Los Angeles 67
Bologna 65
Lauterbourg 60
Jacksonville 59
Cambridge 57
Helsinki 53
Seoul 51
Nanjing 49
Westminster 47
Padova 45
Rome 45
Abidjan 44
Tokyo 43
Lomé 41
Milan 37
Medford 35
Turin 34
Abeokuta 32
Berlin 30
Shenyang 29
Buffalo 28
Da Nang 26
Jinan 26
Florence 25
Frankfurt am Main 25
Guangzhou 24
Haiphong 24
Saint Petersburg 24
Redondo Beach 22
Sofia 21
Mülheim 20
Dearborn 19
Hebei 19
Shanghai 19
Changsha 18
Tianjin 18
Amman 16
Nanchang 15
Vienna 14
Brussels 13
Fremont 13
Hangzhou 13
Kyiv 13
Munich 13
Redwood City 13
São Paulo 13
Des Moines 12
Nuremberg 12
Orem 12
Ravenna 12
San Diego 12
Taiyuan 12
Falls Church 11
Jiaxing 11
Atlanta 10
Brooklyn 10
Bến Tre 10
Hải Dương 10
San Francisco 10
Xi'an 10
Bangkok 9
Bengaluru 9
San Venanzo 9
Warsaw 9
Yubileyny 9
Zhengzhou 9
Can Tho 8
Johannesburg 8
Kunming 8
Phoenix 8
Amsterdam 7
Chicago 7
Falkenstein 7
Haikou 7
Jakarta 7
Totale 5.808
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 470
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer 276
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 275
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 251
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 251
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 240
Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer 233
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 224
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 216
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 210
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 198
Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses 191
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study 188
GemOx and Ovarian Pancreatic Cancer Metastasis (PC) 187
Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs? 185
State of the art biological therapies in pancreatic cancer 182
Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer 179
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 176
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? 174
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 169
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 168
Erratum: β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer (Cancer Cell (2018) 33(1) (75–90.e7), (S153561081730510X) (10.1016/j.ccell.2017.11.007)) 162
Gemox in combination witherlotinib (E) in pancreatic cancer (PC). 160
Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment? 159
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 159
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE 158
Preoperatory Gemcitabine and Oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma 158
The follow-up issues: from the necessity to the opportunity 156
CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS 155
Whole Transcriptome Sequencing Reveals Molecular Prognostic Markers in Pancreatic Adenocarcinoma 154
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? 153
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. 152
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 152
Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience 150
Whole-transcriptome paired-end sequencing and the pancreatic cancer genetic landscape 149
Hedgehog Signaling: from the Cuirass to the Heart of Pancreatic Cancer 148
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 147
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 147
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 147
Locally Advanced Pancreatic Cancer: Is It Possible Pancreatic Resection? A Case Report 144
Useful of Choi’s criteria after neoadjuvant chemoradiotherapy in patients with resectable pancreatic cancer. 142
Long-Term Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Case Report 137
Neoadjuvant Therapy for Resectable Pancreatic Adenocarcinoma: An Interim Report of a Prospective Controlled Randomized Study 137
Prognostic factors in resected pancreatic cancer:a single centre experience 135
Whole genome discovery of genetic alterations carried by pancreatic adenocarcinoma 132
Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Advanced Pancreatic Cancer 128
Whole Transcriptome Sequencing Reveals Somatic HMGCR Mutation in a Case of Pancreatic Adenocarcinoma with Long-Term Therapy Response 128
Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Resectable and Advanced Pancreatic Cancer. 122
New WHO classification for pancreatic endocrine tumours: is time to leave the previous one 120
SNP-Array High Resolution Cytogenetic Analysis of Resectable and Advanced Pancreatic Cancer 116
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: an interim report of a prospective controlled randomized study. 110
Whole genome discovery of genetic alterations in resectable and advanced pancreatic cancer. 110
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 103
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey 102
Role of CA 19-9 Concentration as an Independent Prognostic Factor in Unresectable Pancreatic Ductal Adenocarcinoma (PDCA) Treated with GemOx 100
Resection Margin Involvement in Pancreaticoduodenectomy. A Single Centre Experience 100
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 89
1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study 84
Totale 9.648
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.869
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.869
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022914 0 44 30 70 89 51 13 57 38 107 240 175
2022/20231.238 105 173 69 133 80 102 13 84 169 51 135 124
2023/2024405 26 44 10 37 34 135 17 31 9 21 23 18
2024/20251.251 59 136 98 66 232 56 112 87 25 95 47 238
2025/20263.381 278 282 273 232 323 172 438 106 715 293 139 130
2026/2027191 93 98 0 0 0 0 0 0 0 0 0 0
Totale 9.648